Yes the sales guidance from DNDN management was a massive error...

Yes the sales guidance from DNDN management was a massive error in judgement.

I will be asking Martin how Dubai sales are progressing tomorrow.

We should have phase 11b preliminary data early next year for cvac. The criteria for entry to the stage 111 trial is different again involving less compromised immune systems through chemotherapy which could ( should?) lead to improved immune system response and better clinical data.

DNDN have also been doing studies on prostrate cancer sufferers at earlier stages of diagnosis with a view to bringing provenge into the treatment cycle earlier.

http://seekingalpha.com/article/313272-dendreon-neoact-phase-2-trial-data-appear-interesting

The cancer immunotherapy sector continues to develop. :)